High-value science is developed continuously. Much of it never reaches the market.
(the context)
Universities and research centers generate discoveries with high therapeutic potential every year. The challenge rarely lies in the science itself, but in the ability to turn knowledge into protected, validated pharmaceutical assets ready for global production.
Without adequate technological maturation, scientific governance, and an intellectual property strategy, promising technologies remain confined to academia and never reach their full impact potential.
Between scientific discovery and the pharmaceutical industry, we build assets.
An integrated platform. Two complementary pillars.
Aether Global Pharma and ICT AetherBio+ operate synergistically to transform high-potential science into structured pharmaceutical assets that advance along the development journey and generate value.
ICT AetherBio+ brings together scientific expertise, infrastructure, partners, and resources to advance projects and reduce their technological risk. Aether Global Pharma leads the assets' development and value-creation strategy, integrating intellectual property, regulatory strategy, capital, and positioning for partnerships and licensing.
Together, they connect universities and researchers, specialized capital, and the pharmaceutical industry, creating a structured journey for promising discoveries to advance with greater maturity, consistency, and global potential - expanding industry's access to selected, protected, and progressively developed assets for external innovation.
Two institutional pillars. One integrated strategy.
An institutional architecture to build and add value to pharmaceutical assets.
(platform architecture)
The Aether platform operates through two complementary entities, with distinct functions integrated throughout the assets' development journey. This architecture makes it possible to bring together science, intellectual property, capital, and development strategy in a model oriented toward risk reduction, value creation, and licensing.
Aether Global Pharma is the platform's business pillar and operates as a Pharmaceutical Asset Venture Builder, dedicated to building, developing, and adding value to pharmaceutical assets originating from high-potential science.
The company leads the assets' integrated strategy, bringing together intellectual property, development, capital, and market positioning. It builds partnership, co-development, and licensing opportunities, connecting progressively developed assets to the pharmaceutical industry and specialized capital.
(main functions)
Strategy, management, and value creation for the pharmaceutical asset portfolioOwnership and strategic management of intellectual property assetsStructuring development and value-creation strategiesEngaging private capital and specialized life sciences investorsDeveloping partnerships with the pharmaceutical industryStructuring co-development, licensing, royalty, milestone, and liquidity-event models
ICT AetherBio+ is the platform's scientific and technological pillar, responsible for bringing together expertise, infrastructure, and resources to advance and de-risk high-potential pharmaceutical projects.
As a nonprofit science, technology, and innovation institution, it oversees the projects' scientific governance and builds development strategies aimed at advancing technology readiness. It connects researchers, universities, research centers, and specialized partners, mobilizing scientific and technological capabilities to generate evidence, reduce uncertainty, and prepare projects for their next development stages.
Its work also provides access to national and international funding and scientific cooperation mechanisms, backed by specialized, multidisciplinary governance.
(main functions)
Scientific and technological de-risking aimed at building pharmaceutical assetsScientific governance and structured management of technology-readiness advancementEngagement with universities, research centers, CROs, and specialized partnersStructuring and qualifying scientific projects with translational potentialSecuring and coordinating public funding and non-dilutive resources, both national and internationalGenerating evidence and advancing TRLs to reduce uncertainty and add value to assetsScientific and institutional ecosystem
The Aether platform operates in collaboration with universities, research centers, and scientific and technological institutions that make up a highly qualified ecosystem.
